Definitive Healthcare Corp. (NASDAQ: DH) reported second-quarter 2026 revenue of $55.2 million, a 9 percent decline from the $60.8 million recorded in the same period last year. While the top-line miss reflects ongoing market headwinds, the healthcare data analytics firm generated $11.6 million in unlevered free cash flow, demonstrating operational discipline amidst slowing growth. The company also reported adjusted net income of $7.5 million, down from $9.7 million in Q2 2025, as it navigates a competitive landscape while investing in new AI-driven capabilities.

The divergence between GAAP and non-GAAP metrics highlights the impact of prior-period impairments on current comparables. Definitive Healthcare posted a net loss of $(7.5) million, or (14)% of revenue, compared to a $(9.3) million net loss, or (15)% of revenue, in Q2 2025. This improvement in net loss margin is partly attributable to the absence of significant goodwill impairment charges that weighed heavily on results in previous periods, alongside disciplined cost management.

Financial Performance Overview

Adjusted EBITDA stood at $14.6 million, representing 26 percent of revenue, down from $18.7 million, or 31 percent of revenue, in the prior year quarter. The contraction in adjusted profitability metrics suggests that while the company is maintaining positive cash generation, margin pressure persists as it balances investment in growth initiatives against a shrinking revenue base.

Strategic Initiatives and Customer Wins

Kevin Coop, CEO of Definitive Healthcare, emphasized the launch of Turbo, the company’s new AI-powered healthcare intelligence platform, as a key milestone in its innovation strategy. Coop stated, "We’re encouraged by our second consecutive quarter of year-over-year improvement in net dollar retention, strong win-back momentum across our end markets, and the launch of Turbo... We remain confident that our focus on data quality and customer success is the right path to return to sustained, predictable growth."

The company highlighted specific customer wins validating its premium data positioning. A diversified-business customer returned to Definitive Healthcare in a six-figure, three-year win-back enterprise agreement, illustrating that clients ultimately recognize the cost of inferior datasets outweighs savings from lower-cost alternatives. Additionally, a long-standing population-intelligence customer expanded from an initial test into a total activation commitment of several hundred thousand dollars, signaling rising adoption across its agency ecosystem.

What the Numbers Show

The simultaneous decline in both revenue and adjusted profitability indicates that cost-cutting measures alone are not fully offsetting top-line softness. With adjusted EBITDA margin compressing from 31 percent to 26 percent year-over-year, the company faces a dual challenge of reaccelerating growth while preserving margins. The strong win-back momentum and improved net dollar retention suggest underlying demand remains, but the execution of these gains into full-year revenue growth will be critical. The robust cash flow position provides a buffer for continued investment in Turbo and other growth priorities without immediate liquidity constraints.

Forward Guidance

Looking ahead, Definitive Healthcare provided financial guidance for the third quarter and full year 2026:

• Q3 2026 Revenue: Expected in the range of $54.0 – $55.0 million.
• Q3 2026 Adjusted Operating Income: Expected in the range of $10.5 – $11.5 million.
• Full Year 2026 Revenue: Expected in the range of $220.0 – $222.0 million.
• Full Year 2026 Adjusted Net Income: Expected in the range of $27.0 – $29.0 million.

The guidance implies continued modest revenue declines or flat performance in the near term, with a focus on stabilizing profitability through adjusted operating income and net income targets.

Definitive Healthcare (NASDAQ: DH) has raised its adjusted earnings per share (EPS) guidance for FY2026, signaling stronger-than-expected profitability despite a narrowed revenue outlook. The healthcare data and analytics provider updated its financial projections, lifting the adjusted EPS range from $0.16-$0.19 to $0.18-$0.20. This revised guidance exceeds the consensus analyst estimate of $0.18, indicating management’s confidence in margin expansion or cost efficiencies even as top-line growth expectations are refined.

While the earnings guidance beat estimates, the company simultaneously tightened its sales forecast for FY2026. Definitive Healthcare narrowed its revenue outlook from a previous range of $220.000 million-$226.000 million to $220.000 million-$222.000 million. This narrower band suggests increased certainty around lower-end revenue performance, as the new upper limit of $222.000 million falls below the analyst estimate of $223.449 million. The divergence between improved profitability metrics and conservative revenue guidance highlights a strategic focus on operational efficiency over aggressive top-line expansion.

Guidance Revisions

The updated financial guidance reflects a shift in investor expectations for the company’s fiscal year ending in 2026. The following table compares the revised figures against prior guidance and analyst estimates:

What the Numbers Show

The most material aspect of this update is the decoupling of earnings growth from revenue growth. By raising the adjusted EPS midpoint while lowering the revenue ceiling, Definitive Healthcare implies an improvement in operating margins. The revised EPS range of $0.18-$0.20 suggests that the company expects to generate higher profit per share even if total sales remain at the lower end of the previously projected spectrum. This pattern often indicates successful cost containment measures or a shift toward higher-margin products or services within the healthcare analytics sector. Investors should note that while the bottom line is strengthening, the top-line growth trajectory has been moderated, with the new revenue cap sitting approximately $3.449 million below market expectations.